Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Revenue (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Revenue data on record, last reported at $3.3 million in Q3 2025.

  • For Q3 2025, Revenue rose 16.58% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $10.3 million, up 37.1%, while the annual FY2024 figure was $10.1 million, 29.94% up from the prior year.
  • Revenue reached $3.3 million in Q3 2025 per TNXP's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Revenue topped out at $4.0 million in Q3 2023 and bottomed at $2.0 million in Q2 2025.
  • Average Revenue over 3 years is $2.8 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Revenue: tumbled 37.7% in 2024, then grew 16.58% in 2025.
  • A 3-year view of Revenue shows it stood at $4.0 million in 2023, then tumbled by 35.27% to $2.6 million in 2024, then grew by 27.42% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $3.3 million in Q3 2025, $2.0 million in Q2 2025, and $2.4 million in Q1 2025.